BIOAGE LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 390.12K shares.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 217.83K shares.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 3.22K shares.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 136.87K shares, a 64.50% increase from fiscal 2024.
- BIOAGE LABS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 83.20K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 390.12K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | |
| 2026-03-31 | 217.83K shares 10-Q · filed 2026-05-08 | |
| 2025-12-31 | 136.87K shares 10-K · filed 2026-03-24 | |
| 2024-12-31 | 3.22K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 83.20K shares 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |